Feasibility of using low-cost, byproduct materials as sorbents to remove heavy metals from aqueous solutions

This work investigates the sorption of heavy metals by low-cost, byproducts such as charcoal fines (CF), waste green sand, and rice husk ash, in order to examine the feasibility of their use as alternative filter materials for metal-contaminated waters. The sorption of Cd, Cu, Pb, and Zn was investigated in batch experiments and sorption isotherms were constructed. The three byproducts showed high metal removal efficiencies (>95%, regardless of the metal concentration tested). The highest metal sorption distribution coefficients were obtained for CF, with maximum values within the 105-106 L kg-1 range for all the target metals. The sorption isotherms were satisfactorily fitted using the Freundlich equation and a linear model, the latter only being valid for initial metal concentrations lower than 0.4 mmol L-1. Sorption reversibility was very low, with desorption yields lower than 2% and desorption distribution coefficients often higher than 106 L kg-1. The values of the sorption and desorption parameters indicated that the use of these materials, especially CF, could constitute a low-cost alternative for the remediation of contaminated waters

A "semi-closed" recirculating system for the in situ study of feeding and respiration of benthic suspension feeders

Suspension feeding is one of the most widespread feeding strategies among benthic organisms. However, natural feeding ecology and energetics of benthic suspension feeders are poorly known. The scarcity of field methods, apparatus and protocols that facilitate obtention of reliable in situ data has contributed to this lack of knowledge. A detailed description of an improved semi-closed recirculating system as well as the experimental set up is provided for the study of energetics in benthic suspension feeders. The system, completely submersible and surface-independent, allows us to assess oxygen concentration changes and feeding rates under natural conditions. Methodological examinations are conducted to investigate: a) the circulation of the water within the chamber; b) the time required for the flushing pump to entirely renew the volume of water of the incubation chambers; c) the behavior of the species within the chambers; d) the time of acclimation to the chamber conditions for the different species; e) the maximum decrease in oxygen concentration without affecting respiration rate; f) the time required to detect changes in concentration of the natural food sources. The system and experimental protocol is tested with species from three representative phyla, Porifera, Cnidaria and TunicataThe manuscript was improved by the comments of Fenny Cox. We would like to thanks the assistance of Mikel Zabala, Josep-Maria Llenas and Loïc de Maissonneuve. Support for this work was provided by a RED research contract from the “Generalitat de Catalunya” to R.C., by a postdoctoral fellowship from the “Ministerio de Educación y Cultura” to M.R., by PETRI grant PTR94-0119, by DGICYT grant PB98-0456-C03-01 and by a LEA projectPeer reviewe

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Simple Summary Since the irruption of PARPi in the therapeutic armamentarium for ovarian cancer, concerns regarding post-progression treatment outcomes have emerged, owing to known crossed-resistance mechanisms between PARPi and platinum. In this multicentric retrospective series of ovarian cancer patients, we evaluated chemotherapy results upon progression to maintenance with PARPi in the relapsed setting. We further selected the population of platinum-sensitive patients (according to the classical definition) retreated with platinum (n = 74). In this platinum-sensitive population, overall response rate and survival outcomes of platinum rechallenge after PARPi were similar to historical series of the prePARPi era. However, within this group, analysis according to BRCA status showed that BRCA mutant patients (n = 35) presented higher rates of progression and worse survival outcomes under subsequent platinum than BRCA wild type patients (n = 39), with statistically significant differences. This is the largest real-world data series of ovarian cancer patients treated with platinum rechallenge in the post-PARPi scenario. Background: Despite impressive progression-free survival (PFS) results from PARP inhibitors (PARPi) in ovarian cancer, concerns about their effect on post-progression treatment outcomes have recently arisen, particularly when administered in the relapsed setting. Overlapping mechanisms of resistance between PARPi and platinum have been described, and optimal therapies upon progression to PARPi are unknown. We communicate real-world data (RWD) on outcomes of subsequent chemotherapy upon progression to PARPi used as maintenance in ovarian cancer relapses, particularly focusing on platinum rechallenge, according to BRCA status. Methods: Data from high-grade serous or endometrioid ovarian cancer patients who received subsequent chemotherapy after progression to maintenance PARPi in the relapsed setting, in 16 Catalan hospitals between August 2016 and April 2021, and who were followed-up until July 2021, were included. Endpoints were overall response rate (ORR), and PFS and overall survival (OS) measured from the subsequent chemotherapy starting date. Results: 111 patients were included [46 (41.4%) presented pathological BRCA1/2 mutations, 8 (7.5%) in other homologous recombination-related genes]. Sixty-four patients (57.7%) had received two prior chemotherapy lines, including the one immediately prior to PARPi. PARPi were niraparib (n = 60, 54.1%), olaparib (n = 49, 44.1%), and rucaparib (n = 2, 1.8%). A total of 81 patients remained platinum-sensitive (PS population) after progression to PARPi (when progression-free interval [PFI] was >6 months after the last cycle of prior platinum) [median PFI 12.0 months (interquartile range, IQR, 8.8-17.1)]. Of those, 74 were treated with subsequent platinum regimens, with the following results: ORR of 41.9%, median PFS (mPFS) of 6.6 months (95% CI 6-9.2), and median OS (mOS) of 20.6 months (95% CI 13.6-28.9). Analysis of these 74 patients according to BRCA status showed that PFIs for BRCA mutant and non BRCA-mutant patients were 13.6 [IQR11.2-22.2] and 10.3 [IQR 7.4-14.9] months, respectively (p = 0.010); ORR were 40.0% versus 43.6%, respectively; Rates of progression (as best response) to subsequent platinum were 45.7% versus 17.9%, respectively (p = 0.004); mPFS and mOS were 3.5 (95% CI 2.5-8.6) versus 7.5 months (95% CI 6.5-10.1, p = 0.03), and 16.4 (95% CI 9.3-27.5) versus 24.2 months (95% CI 17.2-NR, p = 0.036), respectively. Conclusion: This is the largest series of real-world data on ovarian cancer patients retreated with platinum in the post-PARPi scenario, separately analyzing BRCA mutant and non-mutant patients, to our knowledge. In our platinum-sensitive population, rechallenge with platinum after progression upon PARPi in the 3rd or later lines for ovarian cancer relapses shows relevant ORR and similar PFS outcomes to historical series of the prePARPi era. However, BRCA mutant patients presented significantly higher rates of progression under subsequent platinum and worse survival outcomes associated with subsequent platinum than non-BRCA-mutant patients

Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012)

OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with acute/recent HIV-1 infection in Barcelona during the period 1997-2012. METHODS: Patients from the "Hospital Clinic Primary HIV-1 Infection Cohort" with a genotyping test performed within 180 days of infection were included. The 2009 WHO List of Mutations for Surveillance of Transmitted HIV-1 Drug Resistance was used for estimating the prevalence of TDR and phylogenetic analysis for subtype determination. RESULTS: 189 patients with acute/recent HIV-1 infection were analyzed in 4 time periods (1997-2000, n=28; 2001-4, n=42; 2005-8, n=55 and 2009-12, n=64). The proportion of patients with acute/recent HIV-1 infection with respect to the total of newly HIV-diagnosed patients in our center increased over the time and was 2.18%, 3.82%, 4.15% and 4.55% for the 4 periods, respectively (p=0.005). The global prevalence of TDR was 9%, or 17.9%, 9.5%, 3.6% and 9.4% by study period (p=0.2). The increase in the last period was driven by protease-inhibitor and nucleoside-reverse-transcriptase-inhibitor resistance mutations while non-nucleoside-reverse-transcriptase inhibitor TDR and TDR of more than one family decreased. The overall prevalence of non-B subtypes was 11.1%, or 0%, 4.8%, 9.1% and 20.3 by study period (p=0.01). B/F recombinants, B/G recombinants and subtype F emerged in the last period. We also noticed an increase in the number of immigrant patients (p=0.052). The proportion of men-who-have-sex-with-men (MSM) among patients with acute/recent HIV-1 infection increased over the time (p=0.04). CONCLUSIONS: The overall prevalence of TDR in patients with acute/recent HIV-1 infection in Barcelona was 9%, and it has stayed relatively stable in recent years. Non-B subtypes and immigrants proportions progressively increased

Gut microbiome signatures linked to HIV-1 reservoir size and viremia control

The potential role of the gut microbiome as a predictor of immune-mediated HIV-1 control in the absence of antiretroviral therapy (ART) is still unknown. In the BCN02 clinical trial, which combined the MVA.HIVconsv immunogen with the latency-reversing agent romidepsin in early-ART treated HIV-1 infected individuals, 23% (3/13) of participants showed sustained low-levels of plasma viremia during 32 weeks of a monitored ART pause (MAP). Here, we present a multi-omics analysis to identify compositional and functional gut microbiome patterns associated with HIV-1 control in the BCN02 trial. Viremic controllers during the MAP (controllers) exhibited higher Bacteroidales/Clostridiales ratio and lower microbial gene richness before vaccination and throughout the study intervention when compared to non-controllers. Longitudinal assessment indicated that the gut microbiome of controllers was enriched in pro-inflammatory bacteria and depleted in butyrate-producing bacteria and methanogenic archaea. Functional profiling also showed that metabolic pathways related to fatty acid and lipid biosynthesis were significantly increased in controllers. Fecal metaproteome analyses confirmed that baseline functional differences were mainly driven by Clostridial es. Participants with high baseline Bacteroidales/Clostridiales ratio had increased pre-existing immune activation-related transcripts. The Bacteroidales/Clostridiales ratio as well as host immune-activation signatures inversely correlated with HIV-1 reservoir size. The present proof-of-concept study suggests the Bacteroidales/Clostridiales ratio as a novel gut microbiome signature associated with HIV-1 reservoir size and immune-mediated viral control after ART interruption. The online version contains supplementary material available at 10.1186/s40168-022-01247-6

Gut microbiome signatures linked to HIV-1 reservoir size and viremia control

Background: The potential role of the gut microbiome as a predictor of immune-mediated HIV-1 control in the absence of antiretroviral therapy (ART) is still unknown. In the BCN02 clinical trial, which combined the MVA.HIVconsv immunogen with the latency-reversing agent romidepsin in early-ART treated HIV-1 infected individuals, 23% (3/13) of participants showed sustained low-levels of plasma viremia during 32 weeks of a monitored ART pause (MAP). Here, we present a multi-omics analysis to identify compositional and functional gut microbiome patterns associated with HIV-1 control in the BCN02 trial. Results: Viremic controllers during the MAP (controllers) exhibited higher Bacteroidales/Clostridiales ratio and lower microbial gene richness before vaccination and throughout the study intervention when compared to non-controllers. Longitudinal assessment indicated that the gut microbiome of controllers was enriched in pro-inflammatory bacteria and depleted in butyrate-producing bacteria and methanogenic archaea. Functional profiling also showed that metabolic pathways related to fatty acid and lipid biosynthesis were significantly increased in controllers. Fecal metaproteome analyses confirmed that baseline functional differences were mainly driven by Clostridiales. Participants with high baseline Bacteroidales/Clostridiales ratio had increased pre-existing immune activation-related transcripts. The Bacteroidales/Clostridiales ratio as well as host immune-activation signatures inversely correlated with HIV-1 reservoir size. Conclusions: The present proof-of-concept study suggests the Bacteroidales/Clostridiales ratio as a novel gut microbiome signature associated with HIV-1 reservoir size and immune-mediated viral control after ART interruption. Video abstract

IL-6 is constitutively expressed during lung morphogenesis and enhances fetal lung explant branching

Previous studies have shown that chorioamnionitis, with increased IL-6, promotes fetal lung maturation and decreases the incidence of respiratory distress syndrome in premature neonates. However, the expression pattern and the effects of IL-6 on fetal lung growth mechanisms remain unknown. IL-6 expression was assessed by in situ hybridization and by real-time PCR between 14.5 and 21.5 d postconception. Normal and nitrofen-induced hypoplastic lung explants were cultured with increasing IL-6 doses or IL-6 neutralizing antibodies. Branching, cellular proliferation (Ki-67) and MAPK phosphorylation in fetal lung explants were analyzed. Pulmonary primitive epithelium expressed IL-6 constitutively throughout all gestational ages, displaying highest levels during earliest stages. In normal and hypoplastic lung explants, IL-6 neutralizing antibodies significantly reduced, whereas IL-6 supplementation induced a biphasic effect (lower doses increased, while the highest dose did not accomplish additional effect) on branching and cellular proliferation. IL-6 enhanced p38-MAPK phosphorylation without changing MEK1/2 and JNK pathways. The present study suggests a physiological role for IL-6 on pulmonary branching mechanisms most likely involving p38-MAPK intracellular signalling pathway

The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

Background: Mortality due to COVID-19 is high, especially in patients requiring mechanical ventilation. The purpose of the study is to investigate associations between mortality and variables measured during the first three days of mechanical ventilation in patients with COVID-19 intubated at ICU admission. Methods: Multicenter, observational, cohort study includes consecutive patients with COVID-19 admitted to 44 Spanish ICUs between February 25 and July 31, 2020, who required intubation at ICU admission and mechanical ventilation for more than three days. We collected demographic and clinical data prior to admission; information about clinical evolution at days 1 and 3 of mechanical ventilation; and outcomes. Results: Of the 2,095 patients with COVID-19 admitted to the ICU, 1,118 (53.3%) were intubated at day 1 and remained under mechanical ventilation at day three. From days 1 to 3, PaO2/FiO2 increased from 115.6 [80.0-171.2] to 180.0 [135.4-227.9] mmHg and the ventilatory ratio from 1.73 [1.33-2.25] to 1.96 [1.61-2.40]. In-hospital mortality was 38.7%. A higher increase between ICU admission and day 3 in the ventilatory ratio (OR 1.04 [CI 1.01-1.07], p = 0.030) and creatinine levels (OR 1.05 [CI 1.01-1.09], p = 0.005) and a lower increase in platelet counts (OR 0.96 [CI 0.93-1.00], p = 0.037) were independently associated with a higher risk of death. No association between mortality and the PaO2/FiO2 variation was observed (OR 0.99 [CI 0.95 to 1.02], p = 0.47). Conclusions: Higher ventilatory ratio and its increase at day 3 is associated with mortality in patients with COVID-19 receiving mechanical ventilation at ICU admission. No association was found in the PaO2/FiO2 variation

XXII Setmana Internacional de Cinema Fomatiu. L’Educació Lliure i el Cinema Formatiu

XXII Setmana Internacional de Cinema Fomatiu: L’Educació Lliure i el Cinema Formatiu. 21 al 25 de novembre de 2016. Sala d'actes. Palau de les heures. Campus Mundet, Universitat de Barcelona.Fa 22 anys vàrem iniciar, arrel de la celebració del centenari del naixement del cinema, una activitat que encara avui mantenim: la SETMANA DE CINEMA FORMATIU. Una activitat per a aprofundir en una estratègia didàctica a partir del model ORA, dissenyat per un col·lectiu de professorat pertanyent al grup GIAD, concretament Saturnino de la Torre, Maria de Borja, Núria Rajadell i Maria Dolors Millan. Després d‟haver superat ja dues dècades seguim oferint aquest punt de trobada entre professorat i estudiants de diferents ensenyaments, amb la finalitat de debatre i reflexionar al voltant d‟una temàtica concreta, i, depenent de la temàtica seleccionada, i eixamplant la col·laboració amb altres institucions i professionals que treballen de manera específica amb la temàtica seleccionada. El Seminari de Cinema Formatiu, depenent del GIAD (Grup d‟Investigació i Assessorament Didàctic) de la Facultat d‟Educació de la Universitat de Barcelona, promou aquesta activitat però és un seminari de treball i de recerca obert a totes aquelles persones que estiguin interessades en el cinema, i puntualment a aquelles persones que estan interessades per la temàtica específica que es tracta al llarg de la Setmana. Alguns estudiants s‟han implicat i han passat a formar part del Seminari que l‟organitza. Aquest és l‟èxit i la raó d‟aquesta activitat, la implicació i la participació, el diàleg i l‟expressió de totes les persones que participen. Aquest any, arrel de l‟interessant debat que existeix en la nostra societat sobre la importància, necessitat i eficiència de l‟actual Sistema Educatiu, i amb la incorporació d‟entitats que es troben més enllà de l‟Administració i que han creat col·lectius per a aprofundir i visibilitzar la innovació educativa a les aules,hem considerat que podria ser interessant conèixer experiències més aviat trencadores del sistema escolar en què ens trobem immersos. Considerem interessant conèixer i reflexionar al voltant de propostes innovadores en el marc de l‟educació i la formació en un escenari complex, obert i global, com és en el que ens trobem immersos en aquests moments. Aquesta setmana comptem amb la col·laboració d‟un equip de professionals de diferents universitats i de diferents escoles catalanes que ens aportaran el seu coneixement des d‟un escenari privilegiat del nostre petit país com és Catalunya. Comptem, a més, amb una sèrie de pel·lícules que es visionaran i debatran en algunes de les classes, i amb una conferenciant que ha estat investigant en el marc de l‟educació lliure a Itàlia i a Catalunya, la Dra. Aurora Bosna